Literature DB >> 17465102

Subcutaneous immunoglobulin for patients with antibody deficiency.

Matthew Helbert1, Alex Farragher.   

Abstract

This article provides an overview on the management of primary immunodeficiency, and discusses the pharmacokinetics of subcutaneous and intravenous immunoglobulin and the relationship between blood levels and therapeutic effects in both treatments. The article will further highlight both treatments' efficacy in preventing infections and the risk of systemic side effects with each treatment.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17465102     DOI： 10.12968/hmed.2007.68.4.206

Source DB:  PubMed          Journal:  Br J Hosp Med (Lond)        ISSN： 1750-8460            Impact factor:   0.825


  2 in total

Review 1.  Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review.

Authors:  Jenny Lingman-Framme; Anders Fasth
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

2.  A Multi‑Center, Open‑Label, Single‑Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency.

Authors:  Manuel Santamaria; Olaf Neth; Jo A Douglass; Gergely Krivan; Robin Kobbe; Ewa Bernatowska; Sofia Grigoriadou; Claire Bethune; Anita Chandra; Gerd Horneff; Michael Borte; Anja Sonnenschein; Pavlina Kralickova; Silvia Sánchez Ramón; Daman Langguth; Luis Ignacio Gonzalez-Granado; Laia Alsina; Montse Querolt; Rhonda Griffin; Carrie Hames; Elsa Mondou; Jeffrey Price; Ana Sanz; Jiang Lin
Journal:  J Clin Immunol       Date:  2022-01-01       Impact factor: 8.542
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.